RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Mariana Gerschenson to Zidovudine

This is a "connection" page, showing publications Mariana Gerschenson has written about Zidovudine.
Connection Strength

0.441
  1. Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St Claire MC, Nagashima K, Harbaugh SW, Harbaugh JW, Olivero OA, Divi RL, Albert PS, Poirier MC. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses. 2004 Jan; 20(1):91-100.
    View in: PubMed
    Score: 0.213
  2. Jao J, Bonner LB, Dobinda K, Powis KM, Sun S, Legbedze J, Mmasa KN, Makhema J, Mmalane M, Kgole S, Masasa G, Moyo S, Gerschenson M, Mohammed T, Abrams EJ, Kurland IJ, Geffner ME. Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study. Clin Infect Dis. 2024 09 26; 79(3):727-733.
    View in: PubMed
    Score: 0.056
  3. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, Shikuma C. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr. 2003 Apr 01; 32(4):370-4.
    View in: PubMed
    Score: 0.050
  4. Jao J, Sun S, Bonner LB, Legbedze J, Mmasa KN, Makhema J, Mmalane M, Kgole S, Masasa G, Moyo S, Gerschenson M, Mohammed T, Abrams EJ, Kurland IJ, Geffner ME, Powis KM. Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana. J Infect Dis. 2022 11 28; 226(11):2002-2009.
    View in: PubMed
    Score: 0.049
  5. Shikuma CM, Bennett K, Ananworanich J, Gerschenson M, Teeratakulpisarn N, Jadwattanakul T, DeGruttola V, McArthur JC, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiat P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. J Neurovirol. 2015 Oct; 21(5):525-34.
    View in: PubMed
    Score: 0.029
  6. Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, Hongchookiat P, Mathajittiphun P, Pinyakorn S, Rungrojrat P, Praihirunyakit P, Gerschenson M, Phanuphak P, Valcour V, Kim JH, Shikuma C. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012; 17(8):1521-31.
    View in: PubMed
    Score: 0.025
  7. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dub? MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support